Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;19(7):1644-1652.
doi: 10.1111/jth.15364. Epub 2021 Jun 6.

Treatment of bleeding in patients with liver disease

Patrick G Northup  1 , Ton Lisman  2 , Lara N Roberts  3
Affiliations

Treatment of bleeding in patients with liver disease

Patrick G Northup et al. J Thromb Haemost. 2021 Jul.

Abstract

Patients with cirrhosis frequently have complex alterations in their hemostatic system. Although routine diagnostic tests of hemostasis in cirrhosis (platelet count, prothrombin time, fibrinogen level) are suggestive of a bleeding tendency, it is now widely accepted that these tests do not reflect hemostatic competence in this population. Rather, patients with cirrhosis appear to have a rebalanced hemostatic system with hypercoagulable elements. Therefore, routine correction of hemostasis laboratory values, for example by fresh frozen plasma or platelet concentrates, with the aim to avoid spontaneous or procedure-related bleeding is not indicated as is outlined in recent clinical guidance documents. However, little guidance on how to manage patients with cirrhosis that are actively bleeding is available. Here we present three common bleeding scenarios, variceal bleeding, post-procedural bleeding and bleeding in a critically ill cirrhosis patient, with specific management suggestions. As patients with cirrhosis generally have adequate hemostatic competence and as bleeding complications may be unrelated to hemostatic failure, prohemostatic therapy is not the first line of management in bleeding patients with cirrhosis, even in the presence of markedly abnormal platelet counts and/or prothrombin times. We provide a rationale for the restrictive approach to prohemostatic therapy in bleeding patients with cirrhosis.

Keywords: antifibrinolytic agents; blood transfusion; platelet transfusion; portal hypertension; prothrombin time.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflict of interests with the material covered in this manuscript.

Figures

FIGURE 1
FIGURE 1
Common sources of bleeding in patients with cirrhosis. Many bleeding events are due to spontaneous mechanical sources such as ruptured esophageal varices while others are related to related to trauma to blood vessels and tissues, often related to medical interventions. The minority of bleeding events are purely due to the hemostatic failure of end stage liver disease. Figure adapted from Northup, et al. Used with permission.
FIGURE 2
FIGURE 2
Evaluation and treatment schema for bleeding in a patient with cirrhosis. Abbreviations: VET: viscoelastic testing.
See this image and copyright information in PMC

References

    1. Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care. 2019;23(1):98. 10.1186/s13054-019-2347-3 - DOI - PMC - PubMed
    1. Muñoz M, Stensballe J, Ducloy‐Bouthors AS, et al. Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. Blood transfus. 2019;17:112‐136. 10.2450/2019.0245-18 - DOI - PMC - PubMed
    1. Spyropoulos AC, Brohi K, Caprini J, et al. Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient‐specific thromboembolic risk. J Thromb Haemost. 2019;17:1966‐1972. 10.1111/jth.14598 - DOI - PubMed
    1. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death. vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH‐2): a randomised, placebo‐controlled trial. Lancet. 2010;376:23‐32. 10.1016/S0140-6736(10)60835-5 - DOI - PubMed
    1. Shakur H, Roberts I, Fawole B, et al. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post‐partum haemorrhage (WOMAN): an international, randomised, double‐blind, placebo‐controlled trial. Lancet. 2017;389:2105‐2116. 10.1016/S0140-6736(17)30638-4 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources